Clinical trial · Interventional
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
Multicenter Randomized Controlled Clinical Trial of Indocyanine Green Molecular Fluorescence Imaging in the Diagnosis and Treatment of Primary Liver Cancer
NCT05160740CI-TRIAL-00056328ICGMFITinPLCunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The of this study is to explore the clinical outcomes of indocyanine green molecular fluorescence imaging in local resection of primary hepatocellular carcinoma (CNLC Ⅰa stage).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Indocyanine green for injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ICG molecular fluorescence imaging guided surgery
- description
- ICG molecular fluorescence imaging will be used in local hepatectomy of primary liver cancer in this group
- interventionNames
- Drug: Indocyanine green for injection
- type
- PLACEBO_COMPARATOR
- label
- No ICG molecular fluorescence imaging guided surgery
- description
- ICG molecular fluorescence imaging will not be used in local hepatectomy of primary liver cancer in this group
- interventionNames
- Drug: Indocyanine green for injection
Primary outcomes (1)
- measure
- 3-year disease free survival rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 66 Years
Show eligibility criteria text
Inclusion Criteria: * First clinical diagnosis of primary liver cancer (China liver cancer staging, CNLC Ia stage); * Child-Pugh grading standard of liver function was GRADE A or B; * 18-66 years old; * Complete clinical case data; * limited surgical methods (local resection); * Voluntarily participate in the study and sign the informed consent. Exclusion Criteria: * There are basic diseases that cannot tolerate surgery (such as severe cardiopulmonary cerebral renal insufficiency); * Tumor thrombus or distant metastasis was found in main portal vein and primary branch, main hepatic vein and branch, main hepatic vein and inferior vena cava by preoperative imaging examination; * planned pregnancy, unplanned pregnancy and pregnancy; * Preoperative child-Pugh grading standard of liver function was Grade C. * Disease researchers that the investigator considers inappropriate to participate in this clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.